Hyperbaric oxygen therapy (HBOT) demonstrates expanding applications in infectious diseases through its multimodal mechanisms.As an adjunctive treatment, HBOT directly exerts antimicrobial effects through oxygen toxicity and reactive oxygen species generation, while indirectly enhances host immunity by improving neutrophil function and promoting tissue repair.Clinical evidence supports its adjunctive use in complex infections including diabetic foot wounds, necrotizing soft tissue infections, COVID-19, and mucormycosis, particularly in hypoxic wounds where conventional therapies show limited efficacy.While current studies are promising, further randomized trials are needed to standardize protocols and confirm efficacy.
Zhang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: